MOLLI Surgical launches OncoPen, elevating precision surgery for breast cancer
DEERFIELD, Ill., April 9, 2024 /PRNewswire/ — MOLLI Surgical continues to push the boundaries of surgical care with the launch of OncoPen™, a minimally invasive surgical tool designed to empower surgeons and improve outcomes for patients affected with breast cancer. The sleek, pen-like wand seamlessly integrates with the award-winning MOLLI® 2 System, offering sophisticated tools for precisely targeting and removing cancerous lesions.
OncoPen represents a significant leap forward in minimally invasive breast surgery. This unique wand offers surgeons unparalleled directional 3D guidance. Unlike traditional techniques, it eliminates the need for wires, providing increased scheduling flexibility for surgeons and a better patient experience. The procedure involves pre-surgical placement of a tiny MOLLI® Marker near the tumor. During surgery, the surgeon is directed using real-time 3D guidance on the MOLLI® Tablet to the precise location of the lesion. This precision allows for targeted lesion removal, smaller surgical incisions, conserving healthy tissue, and potentially improved cosmesis.
Dr. Jaime Alberty, Director of The Comprehensive Breast Center at NYC Health + Hospitals/Kings County, shares enthusiastic insights into the impact of MOLLI Surgical’s innovations in breast cancer surgery, stating, “The OncoPen is truly exciting. The pen-like design complements our workflow seamlessly, further enhancing the capabilities of the MOLLI 2 System. This combination boosts my confidence in our ability to tackle cancer with unmatched precision. It’s not just about technology; these tools empower us to deliver effective and compassionate care.”
The increasing prevalence of breast cancer necessitates advancements in minimally invasive and patient-centric surgical techniques. OncoPen, designed for use with the MOLLI 2 System’s advanced navigation capabilities, addresses this critical need.
“At MOLLI Surgical, our relentless focus is on the patient, placing their well-being at the core of all our efforts,” said Ananth Ravi, President and CEO of MOLLI Surgical. “We’ve dedicated ourselves to solving real clinical challenges, driven by a commitment to making a tangible difference in patient care. We’re profoundly grateful for the opportunity to improve the patient experience and continue to advance the field of surgical oncology with our innovations.”
Louise Temerty, breast cancer survivor and board member of MOLLI Surgical, adds a personal perspective to the company’s mission stating, “From the beginning, enhancing the patient experience with innovative surgical tools has been our guiding star. The OncoPen exemplifies this, leaving no scar behind – a symbol of our dedication to not just physical recovery, but emotional well-being too.”
OncoPen marks a significant advancement in MOLLI Surgical’s commitment to improving surgical accuracy while ensuring procedures are less invasive and enhance the patient experience.
With the OncoPen currently available, MOLLI Surgical is set to significantly impact how cancer surgeries are performed. To learn more and access visuals of the MOLLI OncoPen, please visit our press kit.
About MOLLI Surgical:
MOLLI Surgical started with one patient, who asked if there was a way to make her breast cancer journey better. Her voice led to the creation of our flagship wire and radiation-free technologies — MOLLI® 2 and MOLLI re.markable™. Our innovations are intended to replace outdated procedures to mark lesions for surgical removal through greater precision, efficiency, and cost-effectiveness. We are obsessed with every detail of our design process to ensure surgeons and radiologists have the best possible tools to support an improved patient experience.
MOLLI® has been recognized by TIME as one of 2022’s “Best Inventions” in the Medical Care category and named to Fast Company’s list of “Next Big Things in Tech,” recognizing technological breakthroughs across industries that promise to transform the future. We are proud to build the advanced solutions that patients and physicians prefer. Follow us on Facebook, LinkedIn, X, and YouTube.
Jewish General Hospital Becomes First in Quebec to Adopt MOLLI Surgical’s Breast Cancer Technology
A first in Quebec to embrace benefits of wire-free, radiation-free technology to elevate the patient experience and improve the delivery of care
November 28, 2023 (Montreal, Quebec) – The Jewish General Hospital (JGH), a leader in the treatment and care of breast cancer, is now the first hospital in Quebec to adopt MOLLI Surgical’s portable, wire-free, and radiation-free technology for localizing lesions for breast cancer surgery.
Thanks to support from a donor through the Jewish General Hospital Foundation, the JGH has purchased MOLLI Surgical’s made-in-Canada, MOLLI 2® System.
The MOLLI® System is an innovative technology that allows radiologists to mark cancerous lesions with the MOLLI Marker®, a localization device roughly the size of a sesame seed. Surgeons then use the MOLLI Wand® and MOLLI Tablet® to locate the lesion marked in radiology reliably, eliminating the need for wire-guided localization.
Earlier this year, MOLLI 2® was launched and added a market-leading innovation — true 3D guidance — which lets surgeons know with confidence where they are and the most direct path to the lesion with millimeter precision. MOLLI re.markable™ — a new tool — was also introduced. It helps physicians accurately mark lesions by allowing radiologists and surgeons to reposition a localization marker with minimal impact or discomfort for patients.
“MOLLI 2 is an intuitive, elegant solution in the operating room,” said Dr. Jean-François Boileau, Surgical Oncologist at JGH. “Like the radioactive seed localization method we used before, we can decouple placement and surgery, helping with patient scheduling. But with MOLLI®, we can extend the time between procedures from seven days to 30 and eliminate the nuclear medicine component that creates anxiety for patients and paperwork for hospitals. I look forward to seeing MOLLI in more hospitals across Quebec, giving physicians and residents in training access to this state-of-the-art equipment, and patients the best care available.”
With MOLLI, the localization procedure takes about five minutes and can happen days or weeks before surgery. By “decoupling” localization from surgery, care teams can improve their workflows to create a better, more patient-centred experience and a more efficient experience for clinicians. Without radioactive technology, hospitals avoid expensive equipment and extensive safety regulations around radiation and disposal protocols, making MOLLI more accessible across urban and rural settings.
“We are honoured that the Jewish General Hospital has chosen to work with MOLLI Surgical to address the needs of their patients,” said Ananth Ravi, President and CEO of MOLLI Surgical. “The MOLLI System replaces a complicated and expensive radioactive seed localization approach by making localization precise, affordable, and as comfortable as possible for patients. At MOLLI Surgical, we strive to continually improve the patient experience.”
“Thanks to an exceptional donor, whose vision is to rapidly provide cutting-edge equipment, the Foundation is thrilled to play a role in the introduction of this state-of-the-art procedure. Once again affirming our mission to provide patients in Montreal and the province of Quebec with access to innovative care,” said Bram Freedman, President and CEO of the Jewish General Hospital Foundation.
About the Jewish General Hospital:
The Jewish General Hospital (JGH), repeatedly ranked by Newsweek among the top 3 hospitals in Quebec, among the top 10 in Canada and among the top 125 in the world, is an acute and specialized care McGill University teaching hospital. The JGH has been serving a diverse patient population irrespective of religion, language, or ethnic background since it was founded in 1934.
The Hospital is home to the Segal Cancer Centre, which is recognized internationally for its ground-breaking cancer treatment and research achievements; and the Lady Davis Institute for Medical Research, one of the largest and most influential medical research centres in Canada. The JGH is the hub institution of the regional health authority known as the CIUSSS West-Central Montreal.
About the Jewish General Hospital Foundation:
Since 1969, the mission of the Jewish General Hospital Foundation has been to advance healthcare and medical research for the people of Quebec by supporting Montreal’s Jewish General Hospital. The Foundation provides essential assistance to the Hospital to enhance its extraordinary patient care, further scientific discovery, and acquire innovative medical equipment. We partner with inspired community members to implement a variety of fundraising initiatives to achieve the Hospital’s ambitious goals.
About MOLLI Surgical:
MOLLI Surgical started with one patient, who asked if there was a way to make her breast cancer journey better. Her voice led to the creation of our flagship wire and radiation-free technologies — MOLLI 2® and MOLLI re.markable™. Our innovations are intended to replace outdated procedures to mark lesions for surgical removal through greater precision, efficiency, and cost-effectiveness. We are obsessed with every detail of our design process to ensure surgeons and radiologists have the best possible tools to support an improved patient experience.
MOLLI® has been recognized by TIME as one of 2022’s “Best Inventions” in the Medical Care category and named to Fast Company’s list of “Next Big Things in Tech,” recognizing technological breakthroughs across industries that promise to transform the future. We are proud to build the advanced solutions that patients and physicians prefer. Follow us on Facebook, LinkedIn, X, and YouTube.